Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026)
Precision Biosciences' (DTIL) quarterly Income from Continuing Operations came in at 8575000.0 in Q1 2026, up 59.69% year-on-year from 5369755.82 in Q1 2025, and down 169.19% on a QoQ basis from 12393000.0 in Q4 2025.
Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Income from Continuing Operations data on file, last reported at 8575000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 59.69% year-over-year to 8575000.0 in Q1 2026; TTM through Mar 2026 was 45996000.0, a 22.07% increase from a year earlier, with the FY2025 full-year figure at 193190000.0, down 23.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8575000.0, down from 12393000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for DTIL reached as high as 15566000.0 in Q2 2024 and fell as low as 35863000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 14606529.41 across 5 years, with a median of 13802000.0 in 2023.
- Across the five-year window, Income from Continuing Operations surged 305.3% in 2024 and plunged 586.67% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 12014000.0 in 2022, then retreated by 14.88% to 13802000.0 in 2023, then sank by 72.8% to 23850000.0 in 2024, then soared by 151.96% to 12393000.0 in 2025, then tumbled by 169.19% to 8575000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 8575000.0 in Q1 2026, 12393000.0 in Q4 2025, and 27645000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Precision Biosciences | 184.51 Mn | 156.22 Mn | - | -8.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.58 Mn |
| Dec 31, 2025 | 12.39 Mn |
| Sep 30, 2025 | -27.65 Mn |
| Jun 30, 2025 | -22.17 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -23.85 Mn |
| Sep 30, 2024 | -29.46 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -13.80 Mn |
| Sep 30, 2023 | -10.79 Mn |
| Jun 30, 2023 | -7.58 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -12.01 Mn |
| Sep 30, 2022 | -14.03 Mn |
| Jun 30, 2022 | -35.86 Mn |
| Mar 31, 2022 | -34.23 Mn |
| Dec 31, 2021 | -30.76 Mn |
| Sep 30, 2021 | -22.12 Mn |
| Jun 30, 2021 | 19.55 Mn |